ClinicalTrials.gg
RecruitingNCT03735992Updated Apr 15, 2026

Mind-body Medicine for Patients With Malignant Hematological Diseases

An interventional study of Mind-body medicine group program in Hematologic Neoplasms, sponsored by Universität Duisburg-Essen. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by Universität Duisburg-Essen · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Sep 2017, registered Nov 2018).
  • Started Sep 2017; still recruiting 9 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 65 studies in Hematologic Neoplasms with a site in Germany — 20 open to participants now, 28 under way, 3 of them phase 3. Hematologic Neoplasms · Germany.

Planned enrollment
25th of 50
94 · median 91
Started
2017
with 3 others
No phase
5 of 65
2 open now
Primary completion
2026-12
later than 6 of 27 live
Registered
33rd of 65
by date

Among the 65 studies in Hematologic Neoplasms with a site in Germany, this one is the 25th largest by planned enrollment of the 50 interventional ones that give a count, is one of 4 that started in 2017, is one of 5 with no phase, reaches primary completion later than 6 of the 27 other live ones, and was the 33rd registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

20 of the 65 studies in Hematologic Neoplasms with a site in Germany are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Hematologic Neoplasms with a site in Germany, or all of them as a file.
02

Study summary

This randomized controlled trial aims to investigate the effectiveness of a mind-body group program as a supprtivemanagement strategy for fatigue in patients with malignant hematological diseases.

03

Conditions studied

  • Hematologic Neoplasms

Keywords

  • Hematologic Neoplasms
  • Supportive Therapy
  • Fatigue
  • Mind-body medicine
  • Complementary and alternative medicine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with malignant hematological diseases in complete remission after primary chemotherapy and/or radiation
  • Physical and mental ability to attent 8 of 11 group units

Exclusion criteria

Exclusion Criteria:

  • Chemotherapy, radiation, or rehabilitation programm during the study period
  • Pregnancy
  • Participation in other studies with behavioral interventions during the study period
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
94 participants (estimated)

Study arms

  • Experimental
    Mind-body medicine group program

    Patients recieve an 11-week mind-body medicine group program including elements of mindfullness based stress reduction (MBSR), yoga, and education + treatment as usual.

    Behavioral: Mind-body medicine group program

  • No intervention
    Wait list

    Treatment as usual.

Interventions

  • BehavioralMind-body medicine group program

    The group program is mainly based on MBSR. It further integrates elements of the mind-body medicine cancer program of the Benson-Henry Mind/Body Medical Institute at Harvard Medical School which is rooted in psychoneuroendocrinology and focuses on relaxation techniques, exercise, cognitive restructuring, diet, and social support. In addition, naturopathic methods of selfregulation and self-care are incorporated.

06

What researchers measure

Primary outcomes

  1. General Fatigue

    Multidimensional Fatigue Inventory (MFI) - General Fatigue Subscale

    Time frame: week 12

Secondary outcomes

  1. General Fatigue

    Multidimensional Fatigue Inventory (MFI) - General Fatigue Subscale

    Time frame: week 24

  2. Physical Fatigue

    Multidimensional Fatigue Inventory (MFI) - Physical Fatigue Subscale

    Time frame: week 12

  3. Physical Fatigue

    Multidimensional Fatigue Inventory (MFI) - Physical Fatigue Subscale

    Time frame: week 24

  4. Reduced Activity

    Multidimensional Fatigue Inventory (MFI) - Reduced Activity Subscale

    Time frame: week 12

  5. Reduced Activity

    Multidimensional Fatigue Inventory (MFI) - Reduced Activity Subscale

    Time frame: week 24

  6. Reduced Motivation

    Multidimensional Fatigue Inventory (MFI) - Reduced Motivation Subscale

    Time frame: week 12

  7. Reduced Motivation

    Multidimensional Fatigue Inventory (MFI) - Reduced Motivation Subscale

    Time frame: week 24

  8. Mental Fatigue

    Multidimensional Fatigue Inventory (MFI) - Mental Fatigue Subscale

    Time frame: week 12

  9. Mental Fatigue

    Multidimensional Fatigue Inventory (MFI) - Mental Fatigue Subscale

    Time frame: week 24

  10. Qaulity of life

    Functional Assessment of Cancer Therapy - General (FACT-G)

    Time frame: week 12

  11. Qaulity of life

    Functional Assessment of Cancer Therapy - General (FACT-G)

    Time frame: week 24

  12. Depression

    Hospital Anxiety and Depression Scale - Depression subscale (HADS-D)

    Time frame: week 12

  13. Depression

    Hospital Anxiety and Depression Scale - Depression subscale (HADS-D)

    Time frame: week 24

  14. Anxiety

    Hospital Anxiety and Depression Scale - Anxiety Subscale (HADS-A)

    Time frame: week 12

  15. Anxiety

    Hospital Anxiety and Depression Scale - Anxiety Subscale (HADS-A)

    Time frame: week 24

  16. Stress

    Perceived Stress Scale (PSS)

    Time frame: week 12

  17. Stress

    Perceived Stress Scale (PSS)

    Time frame: week 24

  18. Sleep

    Pittsburgh Sleep Quality Index (PSQI)

    Time frame: week 12

  19. Sleep

    Pittsburgh Sleep Quality Index (PSQI)

    Time frame: week 24

  20. Physical activity

    Motion sensor (activPAL3, Pal Technologies, Glasgow, Schottland)

    Time frame: week 12

  21. Physical activity

    Motion sensor (activPAL3, Pal Technologies, Glasgow, Schottland)

    Time frame: week 24

  22. Fatigability

    30-Second Chair Stand Test

    Time frame: week 12

  23. Fatigability

    30-Second Chair Stand Test

    Time frame: week 24

  24. Adverse Events

    Number of patients with adverse events

    Time frame: week 12

  25. Adverse Events

    Number of patients with adverse events

    Time frame: week 24

Other outcomes

  1. Treatment Expectation

    Visual Analogue Scale (VAS)

    Time frame: week 0

  2. Treatment Satisfaction

    Client Satisfaction Questionnaire (CSQ)

    Time frame: week 12

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Upon reasonable request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2017 (actual). Primary completion is estimated for Dec 2026, 111 months after the start.

Of 186 non-industry interventional studies with no phase under Hematologic Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 125. This study's planned 111 months is above that.

Counting every sponsor, half of 192 studies reached it within 40 months; a quarter within 21 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2018
First posted
Nov 8, 2018
StartActual
Sep 6, 2017
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03735992
Lead sponsor
Universität Duisburg-Essen
Collaborators
Robert Bosch Medical Center
Responsible party
Holger Cramer (Research Director, Universität Duisburg-Essen) — Principal investigator
First posted
Nov 8, 2018
Start date
Sep 6, 2017
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 15, 2026

Study contacts

Holger Cramer, PhD
Contact
holger.cramer@med.uni-tuebingen.de
+4971181017860
Heidemarie Haller, PhD
Contact
heidemarie.haller@uk-essen.de
+4920172377382
Gustav Dobos, Prof. MD
study director · Center for Integrative Medicine and Health, University Hospital Essen, University of Duisburg-Essen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion